CMV 2012 - combined 4th Congenital Cytomegalovirus Conference and 14th Internatio

CMV 2012 - 第四届先天性巨细胞病毒会议和第 14 届国际巨细胞病毒会议合并

基本信息

批准号：
8400272
负责人：
DEBORAH Hye SPECTOR
金额：
$ 1.3万
依托单位：
PUBLIC HEALTH FOUNDATION ENTERPRISES
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-01 至 2013-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8400272
关键词：
Academia Acquired Immunodeficiency Syndrome Affect Angioplasty Antiviral Agents Area Atherosclerosis Award Awareness Belief Birth California Clinic Clinical Collaborations Congenital Abnormality Cost Savings Cytomegalovirus Development Disease Educational workshop Epidemiology Faculty Family Fertilization Fostering Funding Goals Government Government Agencies Grant Health Health Care Costs Hematopoietic Human Immune response Immunity Immunocompromised Host Impairment Individual Industry Infant Infectious Agent Infusion procedures International Laboratories Lead Medical Medical Students Medicine Mission Molecular Molecular Virology Morbidity - disease rate Neonatal Screening Newborn Infant Organ Pathogenesis Patients Peer Review Physicians Play Postdoctoral Fellow Prevalence Prevention Research Research Personnel Role San Francisco Scientist Societies Students Therapeutic Translational Research Translations Transplant Recipients Transplantation Travel Vaccines Vascular Diseases Viral Virus Virus-Cell Membrane Interaction Work abstracting base congenital cytomegalovirus congenital infection cost cost effective disability improved meetings mortality pathogen public education public health relevance restenosis skills success symposium therapeutic vaccine therapy development tumor

项目摘要

Description (as provided by the applicant): Human cytomegalovirus (HCMV) is the major viral cause of birth defects, and its impact on health care costs is enormous. Approximately 1% of newborns are infected, and of the 13% that are symptomatic at birth, 50% will have permanent impairment. At least 14% of asymptomatic infants will later show disabilities. HCMV is also a serious problem in immunocompromised individuals and has been associated with the development of transplant-associated vascular disease and restenosis following angioplasty. Additionally, it has been proposed that HCMV may play a role in the development of atherosclerosis and the pathogenesis of several types of tumors. The overarching goal of this R13 conference grant is to enable junior investigators (graduate/medical students and postdoctoral fellows, junior faculty) to attend the CMV 2012 Workshop. Travel awards - using funds generated by this application - will be awarded to laboratories of U.S.-based trainees and junior faculty based on peer reviewed scoring of submitted abstracts. CMV 2012 is a unique meeting in that it combines the 4th Congenital CMV Conference and the 14th International CMV/Betaherpesvirus Workshop into a unified conference. The mission of CMV 2012 is to bring together basic scientists, physician scientists, clinicians, representatives from industry and government, and families affected by congenital CMV infection in a forum where there can be a broad exchange of diverse ideas and extensive cross-fertilization of new concepts that lead to a better understanding, prevention, and/or treatment of CMV disease. The increasing emphasis on translational research with the goal of advancing medicine and human health has made it imperative to bring these different groups together. The CMV 2012 Workshop will be held October 29th to November 2nd, 2012 at the Mission Bay Conference Center in San Francisco, California. The areas of focus of both the Congenital CMV Conferences and the International CMV/Betaherpesvirus Workshop will be well-represented at CMV 2012. There are four coequal aims of this meeting. Aim 1 is to facilitate the highest level of scientific excellence with a combination of speakers who are internationally recognized and established leaders in the field, as well as younger investigators whose work is at the cutting edge. Aim 2 emphasizes the research that is highly relevant to important clinical questions and has potential for translation into medical practice. Aim 3 is to foster new collaborations and partnerships between industry, basic and clinical scientists, and government agencies. Aim 4 promotes public education and awareness of the prevalence of congenital CMV infection and impact on society. Public Health Relevance: Human cytomegalovirus (CMV) is the leading cause of birth defects associated with an infectious agent. Moreover, it is a major cause of morbidity and mortality in immunosuppressed patients, including organ and hematopoietic transplant recipients, and AIDS patients. Significant effort in academia, the clinic and industry is being devoted to improve therapies and develop effective vaccines against these viruses. CMV 2012 will be the preeminent venue devoted solely to the broad range of topics encompassing the clinical, virological, molecular, immunological, and societal aspects of this important human pathogen.

描述（申请人提供）：人类巨细胞病毒（HCMV）是出生缺陷的主要病毒原因，其对医疗保健成本的影响是巨大的。大约有1％的新生儿被感染，在出生时有症状的13％中，有50％的新生儿将有永久性损害。至少有14％的无症状婴儿以后会表现出残疾。 HCMV在免疫功能低下的个体中也是一个严重的问题，并且与血管成形术后移植相关的血管疾病和再狭窄的发展有关。此外，已经提出HCMV可能在动脉粥样硬化的发展和几种类型的肿瘤的发病机理中发挥作用。这项R13会议赠款的总体目标是使初级调查人员（研究生/医学生和博士后研究员，初级教师）参加2012年CMV 2012研讨会。使用本申请生成的资金的旅行奖将根据同行评审的提交摘要评分，将授予美国学员和初级教师的实验室。 CMV 2012是一次独特的会议，因为它结合了第四届先天性CMV会议和第14届国际CMV/Betaherpesvirus研讨会，并将其与统一会议结合在一起。 CMV 2012的使命是将基础科学家，医师科学家，临床医生，工业和政府的代表以及受先天性CMV感染影响的家庭汇集在一起，在一个论坛上，可以广泛交流多样化的思想和广泛的交叉杂交新概念，从而导致更好的理解，预防，预防和/或治疗CMV疾病。越来越强调转化研究的目标是推进医学和人类健康，因此必须将这些不同的群体融合在一起。 2012年CMV研讨会将于2012年10月29日至11月2日在加利福尼亚州旧金山的Mission Bay会议中心举行。先天性CMV会议和国际CMV/betaherpesvirus研讨会的重点领域将在CMV 2012中得到很好的代表。这次会议有四个同时的目标。目标1是通过在该领域获得国际认可和成熟的领导者以及工作在最前沿的年轻调查员的演讲者的组合，以促进最高水平的科学卓越水平。 AIM 2强调了与重要临床问题高度相关的研究，并且有可能转化为医学实践。目标3是在行业，基础科学家和政府机构之间建立新的合作和伙伴关系。 AIM 4促进了公共教育和对先天性CMV感染的普遍性和对社会影响的认识。公共卫生相关性：人类巨细胞病毒（CMV）是与传染药有关的先天缺陷的主要原因。此外，这是免疫抑制患者的发病率和死亡率的主要原因，包括器官和造血移植受者以及艾滋病患者。在学术界的巨大努力，诊所和工业旨在改善疗法并针对这些病毒开发有效的疫苗。 CMV 2012将是专门针对这种重要人类病原体的临床，病毒学，分子，免疫学和社会方面的广泛主题的杰出场所。